GLP-1 drugs and plastic surgery risks

A narrative review published in Aesthetic Plastic Surgery on 15 June 2026 pulls together what surgeons currently know about operating on patients who use GLP-1 receptor agonists such as semaglutide. The short version: delayed gastric emptying raises aspiration risk, rapid weight loss can strip lean mass in ways that change body-contouring outcomes, and wound complication rates appear higher in active users^[1].

Perioperative risks the review flags

GLP-1 receptor agonists slow stomach emptying as part of their mechanism of action. That pharmacological effect is what helps patients feel full longer, but it creates a specific problem for anaesthesia teams: a patient who has fasted according to standard pre-surgical protocols may still have residual gastric contents at induction. Venza and Venza note that some patients retain food despite overnight fasting, and they recommend individualised aspiration-risk evaluation rather than relying on generic fasting windows^[1].

The practical implication is that surgeons and anaesthesiologists need to coordinate on GLP-1 status well before the day of surgery. Standard pre-operative questionnaires do not always ask specifically about weight-loss medications, and the review argues that this is a gap worth closing, particularly as GLP-1 prescriptions continue to rise.

On wound healing, the review cites higher wound dehiscence rates in semaglutide users compared with matched controls (5.19% versus 2.78%). A separate retrospective study of aesthetic abdominoplasty published in the same journal found that patients who continued semaglutide through surgery had a 45% complication rate, including wound separation, infection and prolonged drainage. Those who discontinued four weeks before surgery had a rate comparable to patients who had never used the drug (roughly 10% in both groups)^[2].

The sarcopenic morphology problem

Rapid weight loss on GLP-1 agonists does not selectively remove fat. A share of the lost mass is lean tissue, including skeletal muscle. The review uses the term "sarcopenic morphologies" to describe patients who present for body contouring with reduced muscle volume beneath loose skin. For plastic surgeons, this combination changes the tissue planes and may limit what a contouring procedure can achieve^[1].

The clinical consequence is that a patient who has lost 15% of body weight on semaglutide is not the same surgical candidate as a patient who lost the same proportion through diet and exercise over a longer period. Tissue quality, vascularity and the ratio of fat to muscle all differ, and the review argues that operative planning needs to account for this. Surgeons may need to adjust the extent of tissue resection, plan for different wound-closure tension, and set different expectations with the patient about what the final result will look like.

What the review does not answer

The authors are candid about the gaps. Most of the evidence they cite comes from retrospective case series, not prospective controlled trials. The optimal discontinuation window before elective surgery is not settled by high-quality data. The 2024 American Society of Anesthesiologists consensus suggested holding GLP-1 agonists before elective procedures, but the exact timing remains debated, and the review points out that aesthetic-specific prospective research is limited^[1].

We also do not yet know whether the wound-healing concerns apply equally to all GLP-1 agonists or primarily to semaglutide, which dominates the published case literature. Tirzepatide, liraglutide and the investigational triple agonists have far less surgical-outcome data behind them. The review itself is a narrative synthesis, not a systematic review with meta-analysis, so the strength of any individual finding depends on the quality of the underlying studies, most of which are small and retrospective.

Where this sits for readers

If you are considering body contouring after weight loss on a GLP-1 agonist, the review reinforces a practical point: tell your surgical team exactly what you are taking and when your last dose was. The coordination between prescriber, surgeon and anaesthesiologist matters more than any generic rule about when to stop the medication.

The broader context is that GLP-1 prescribing has grown faster than the surgical evidence base behind it. Millions of patients have started these drugs in the past three years, and a growing subset of them will seek body contouring once the weight is off. Plastic surgery literature is catching up, but for now the data is early-stage and the clinical guidance is evolving. For more on how semaglutide works, its adverse-event profile, and how it is regulated by country, see our semaglutide overview page.